|
Author
|
Year
|
Countr
|
Follow-Up
|
Chemo regime
|
No. chemoth
|
Surgery Type(%)
|
Age
|
Tumor Size (cm)
|
Histological Type(%)
|
Margin
|
LR
|
DFS
|
OS
|
MS
|
|---|
|
BCS
|
M
|
Be
|
Bo
|
M
|
< 1 cm (%) (positive)
|
> 1 cm (%) (negative)
|
|---|
|
Chaney,
|
2000
|
USA
|
47 m
|
doxorubicin- ifosfamide ifosfamide 4300 mg
|
4
|
47
|
53
|
41(median)
|
4
|
/
|
20
|
80
|
(1)
|
(99)
|
0
|
0
|
4
|
4
|
|
Guillot,
|
2011
|
France
|
12.65 m
|
Adriamycin 100 mg *6
|
9
|
97
|
3
|
44(median)
|
3
|
/
|
/
|
100
|
28
|
72
|
2
|
6
|
6
|
2
|
|
Morales
|
2007
|
Mexico
|
15 m
|
Doxorubicin + dacarbazine
|
17
|
23.5
|
76.5
|
42(median)
|
13
|
/
|
/
|
100
|
(24)
|
(76)
|
6
|
/
|
14
|
10
|
|
Wang, F.
|
2014
|
China
|
NA
|
NA
|
8
|
61.4
|
38.6
|
49(mean)
|
5
|
/
|
/
|
100
|
NA
|
NA
|
/
|
5
|
6
|
/
|
- Chemo-Chemotherapy; BCS breast conserving surgery, M mastectomy, Be benign, Bo borderline, LR local recurrence, DFS disease-free survival, OS overall survival, MS metastasis, NA not available
